Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma
Hamadani, M Collins, P Samaniego, F Spira, I Davies, A Radford, John A Caimi, P Menne,T Boni, J Cruz, H
Hamadani, M
Collins, P
Samaniego, F
Spira, I
Davies, A
Radford, John A
Caimi, P
Menne,T
Boni, J
Cruz, H
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Hamadani M, Collins G, Samaniego F, Spira A, Davies A, Radford J, et al.Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood. 2018;132.